BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 09, 2005
 |  BioCentury  |  Product Development

Here's CNTF in your eye

Like many other neurotrophic factors, ciliary neurotrophic factor (CNTF) has disappointed over the years. Amgen Inc. dropped development in 1997 after trying it in amyotrophic lateral sclerosis, while Regeneron Pharmaceuticals Inc. discontinued work in 2003 after its Axokine second-generation CNTF failed in obesity trials. Neurotech SA, which licensed rights to ophthalmic indications from AMGN in 2002, last week reported the first fruits of its work in an orphan ophthalmic indication: retinitis pigmentosa.

In a six-month open-label...

Read the full 373 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >